Work

Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease

Year: 2023

Type: review

Abstract: Vision loss causes a significant burden on individuals and communities on a financial, emotional and social level. Common causes include age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and retinitis pigmentosa (RP; also known as 'rod-cone dystrophy'). As the population continues to grow and age globally, an increasing number of people will experience vision loss. Hence, there is an urgent need to develop therapies that can curb early pathological events. The broccoli-derived compound, sulforaphane (SFN), is reported to have multiple health benefits and modes of action. In this review, we outline the preclinical findings on SFN in ocular diseases and discuss the future clinical testing of this compound.

Source: Drug Discovery Today

DOI: 10.1016/j.drudis.2023.103718

Authors: Faith A.A. Kwa, Bang V. Bui, Bruce R. Thompson, Lauren N. Ayton

Institutions: Swinburne University of Technology, The University of Melbourne, The Royal Victorian Eye & Ear Hospital, Centre for Eye Research Australia

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,820